Cannabis Law and Access in Belgium

Fourteen grams. That's the threshold Belgium's federal guidelines historically used to distinguish personal-use possession from intent to supply , a number that says a lot about how Belgian cannabis policy works in practice: cautious, incremental, and frequently caught between federal law and local enforcement discretion.

I've spent a fair bit of time lately reading EU member-state cannabis frameworks for a comparative piece on access pathways. Belgium is genuinely interesting because it occupies a middle lane that many countries eventually end up in: not fully decriminalised, not legalised, but with a medical access system that has matured considerably since the early 2010s. For Australian readers , this is Belgian law, not Australian law. None of this describes what is legal here under the Poisons Standard or TGA regulations. I'll flag AU context where it's useful.

The legal framework: what Belgian federal law actually says

Cannabis in Belgium remains a controlled substance under the 1921 Act on the Traffic in Narcotic Substances (as substantially amended). Possession, cultivation, and supply of cannabis are all technically illegal. But the story doesn't end there, because Belgian enforcement is filtered through a series of ministerial circulars , most significantly the 2005 circular from the College of Prosecutors-General; that established a de facto toleration policy for personal adult possession of up to 3 grams (or one female plant at home).

That 3-gram threshold replaced the older 14-gram figure, reflecting a tightening of informal policy rather than a change in the underlying criminal law. Possession below the threshold is treated as the lowest enforcement priority: police can record the fact but are not required to pursue prosecution. Above the threshold, or where possession is linked to public nuisance or sales to minors, the full force of the criminal code applies. So Belgium is decriminalised in practice, not in statute, a distinction that matters a great deal if you're trying to understand the system from a regulatory angle.

Cultivation beyond a single personal plant is an offence. There is no licensed adult-use retail market. The cannabis social club model that emerged in Spain and elsewhere never received a formal legal basis in Belgium, though clubs have operated in grey zones and attracted ongoing legal attention.

Medical cannabis in Belgium: a regulated but limited access pathway

Belgium established its medical cannabis programme through Royal Decree in 2018, with the first licensed domestic cultivation commencing under oversight from the Federal Agency for Medicines and Health Products (FAMHP, in French, l'AFMPS). The FAMHP is the rough Belgian equivalent of Australia's TGA: it oversees marketing authorisations, product standards, and import licences.

The key product that reshaped Belgian medical access is Bedrocan-origin standardised flower and extract, imported under licence and dispensed via registered pharmacies on a named-patient basis. To receive medical cannabis, a Belgian patient requires a prescription from a registered physician; the product must be dispensed at a compounding pharmacy or authorised outlet. There is no over-the-counter pathway for THC-containing products.

Cannabidiol sits in a different regulatory position. CBD products with a THC content below 0.2% (aligned to EU hemp rules) are sold in specialist shops and pharmacies across Belgium, classified closer to a food supplement than a medicine; though the FAMHP has signalled ongoing scrutiny of novel food and health claim issues. The line between a hemp wellness product and a medicinal product is not always clear, and the agency has issued guidance letters warning that unregistered CBD products making health claims may fall under the Medicines Act. I'd argue that ambiguity is a structural problem the EU still hasn't fully resolved, not just a Belgian one.

Hemp, the 0.2% rule, and what cannabinoids are in scope

Belgian hemp cultivation is permitted under EU common agricultural policy rules, with varieties limited to those on the EU common catalogue and THC content capped at 0.2% in the growing crop. Farmers apply through the Federal Public Service for Agriculture (SPF Agriculture). Industrial hemp grown this way is used for fibre, seed oil, and, increasingly, CBD extraction.

From a cannabinoid science perspective, hemp biomass contains far more than just CBD and trace THC. Minor cannabinoids including CBG, CBN, and CBC are present in varying concentrations depending on cultivar, harvest timing, and post-harvest processing. Terpene profiles; including beta-caryophyllene, myrcene, and linalool, vary considerably between strains. Whether those compounds interact in ways described by the entourage effect hypothesis remains an active area of research; the regulatory frameworks in Belgium (and Australia) do not yet classify products based on it.

Products described as full-spectrum or broad-spectrum on Belgian pharmacy shelves are subject to the same evidence and labelling requirements as any other health product. The FAMHP has been consistent that marketing claims must be substantiated.

Enforcement reality and the political debate

Belgium's federal structure complicates drug enforcement. The country operates under a split competency model: the federal government sets criminal law, but public health policy, including drug use support; is a shared or regional matter across the Flemish, Walloon, and Brussels-Capital regions. What this means in practice is that two people caught with the same amount of cannabis in Ghent and Liège might have meaningfully different experiences depending on the local prosecutor's policy priorities.

There have been successive parliamentary debates about moving toward a regulated adult-use market, most seriously in the 2019–2024 De Croo government period. A coalition agreement section referenced "controlled regulation" of cannabis, and a parliamentary working group published recommendations in 2022 that pointed toward a pilot legalisation model. As of 2024, no legislation has passed. The political fragility of Belgian coalition governments, they held the world record for the longest without a seated government after the 2010 elections, which I only know because I fell down a Wikipedia rabbit hole on a long road ride last winter, means drug law reform can stall for years even with majority sentiment behind it.

How Belgium compares with AU access pathways

Australian readers familiar with our own system will notice both similarities and differences. In Australia, medicinal cannabis products containing THC are prescription-only medicines; Schedule 8 (Controlled Drug) under the Poisons Standard, accessed via a specialist or GP under the TGA's Special Access Scheme or through an Authorised Prescriber. Products must be listed on or approved via the ARTG, or accessed under specific approval pathways. See our ARTG glossary entry for how that works.

Belgium's named-patient prescription model for medical cannabis is structurally similar to elements of Australia's SAS Category B pathway, though the product approval and manufacturing oversight systems differ. Both countries require products to meet Good Manufacturing Practice standards; both restrict THC-containing products strictly to the medical pathway. Neither has a legal adult-use retail market.

Where Belgium differs is in its de facto decriminalisation of small-quantity personal possession, something Australia has not adopted at the federal level, though the ACT's personal use reforms (effective 2020) represent a notable local exception worth a separate article.

Where things stand as of 2024–2025

Belgium formed a new federal government in late 2024 following prolonged coalition negotiations. The new coalition agreement's position on cannabis reform is, at the time of writing, not yet fully articulated in legislation. The FAMHP continues to regulate medical cannabis access; the 0.2% THC hemp rules remain aligned to EU standards; and the informal decriminalisation regime for personal possession persists under the existing prosecutorial circular framework.

If you're researching EU cannabis regulation more broadly, the EMCDDA (now folded into the European Union Drugs Agency, EUDA) publishes annual country drug reports that are the most reliable source for tracking Belgium's evolving policy landscape. Not glamorous reading, honestly, but it's the kind of thing I find genuinely useful.

A note for Australian readers: Nothing in this article describes what is legal in Australia. Australian law on cannabis is determined by the Poisons Standard (a legislative instrument under the Therapeutic Goods Act 1989), state and territory drug laws, and TGA regulations. If you have questions about legal access to medicinal cannabis in Australia, speak with a registered medical practitioner.

Sources

• Loi du 24 février 1921 concernant le trafic des substances vénéneuses; Belgian Official Gazette (Belgisch Staatsblad)
• Medical Cannabis, Federal Agency for Medicines and Health Products (FAMHP)
• Belgium Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA/EUDA)
• Cannabis Policy in Europe: Recent Developments; NCBI/PubMed Central

, Marcus Hale, Regulatory researcher, TGA & access law

]]>